Cedars-Sinai used a nursing education framework to shift a 63-bed oncology unit to a progressive care model, improving ...

A quality improvement project at Sylvester Comprehensive Cancer Center shows that structured education enhances nurse triage ...

FDA approves atezolizumab and a companion diagnostic for adjuvant treatment of MIBC in patients with detected circulating tumor DNA after surgery. The US Food and Drug Administration (FDA) has ...

New data from the ONS Congress suggest that chemotherapy-induced peripheral neuropathy may persist for years in survivors of ...

Jill Winther earned the 2026 Extraordinary Healer® Award for her leadership, advocacy and dedication to oncology nursing. The ...

The FDA approved oral decitabine/cedazuridine and venetoclax for AML. Research showed a 41.6% complete remission rate in ...

The FDA approved sonrotoclax for R/R mantle cell lymphoma. Nurses must manage a 4-week dose ramp-up to prevent TLS for patients after prior BTK therapy. Oncology nurses have a new therapeutic option ...

A landmark study led by researchers at Keck Medicine of USC, recently published in the Journal of Vascular Surgery, indicates ...

MD Anderson’s trial uses psilocybin to help oncology patients overcome anxiety and depression during maintenance therapy. For ...

Learn about the FDA approval of vepdegestrant (Veppanu), the first PROTAC for ESR1-mutated breast cancer, including nursing priorities and side effects. On May 1, the FDA granted approval to ...

FDA approved zenocutuzumab-zbco for post-systemic-therapy, NRG1 fusion–positive unresectable/metastatic cholangiocarcinoma, addressing an ultra-rare molecular ...

HR+/HER2- breast cancer is the most common subtype of the disease, representing approximately 70% of all breast cancer cases.